Mepiprazole is a psychotropic pyrazole derivative. Mepiprazole is a serotonin reuptake inhibitor and adrenolytic. In clinical studies, it demonstrated anxiolytic properties.

Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.

Brocrinat is an ethacrynic acid derivative with diuretic activity. Chronic dosing with Brocrinat does not increase plasma uric acid suggests that therapeutically, Brocrinat as a diuretic may be useful in patients where control of plasma uric acid is desirable..

Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.

Cyclobutoic acid is a synthetic analog of mevalonic acid, developed by the Italian company Farmitalia Carlo Erba SPA. The compound inhibited the incorporation of [14C] into CO2, fatty acids and cholesterol, and was used for the treatment of hepatic deficiency.

Imanixil (also known as HOE-402) was developed as a potent cholesterol-lowering compound, which inhibits VLDL production, and consequently attenuates atherosclerosis development. This drug participated in phase I clinical trial for the treatment of hyperlipidemia, however, this study was discontinued.

Sulfaloxic acid is a benzamide derivative patented by Chemische Fabrik von Heyden A.-G. as an antibacterial agent.

Etoxeridine (Carbetidine or Wy2039), a piperidine derivative, is a narcotic analgetic.

Droxacin is quinolone antibiotic. It is topoisomerase inhibitor.